---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-187243"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:52:48.884744+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency

## Summary
- Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).
- Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.
- No assurance given that company will meet MVLS requirement or maintain other listing standards.

## SEC filing metadata
- accession: 0001193125-26-187243
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/0001193125-26-187243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/d623526d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-187243
- JSON: https://secwatch.observer/filing/0001193125-26-187243.json
- Plain text: https://secwatch.observer/filing/0001193125-26-187243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.